RTTNews汇总美股生物科技股当日大涨个股，核心信息均已在周一收盘价中反映

Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquired
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Blockchain
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
World
White House
Elections
General News
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Corp. News
Market News
Health News
Entertainment News
Music News
TODAY'S TOP STORIES
By
Prabha Kurup
✉
|
Published:
7/27/2026 11:29 PM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
Today's top biotech gainers include Entera Bio, following an oversubscribed private placement financing; Gossamer, which is progressing toward a planned Seralutinib NDA submission in September; First Tracks, which has been firing on all cylinders since its Nasdaq debut; and Forte Biosciences, following its agreement to be acquired by argenx, among others.
Read on…
ENTX Soars on Oversubscribed Financing
Entera Bio Ltd. (
ENTX
), a clinical-stage company, led the pack of gainers on Monday, with shares soaring more than 90%.
The company announced that it has entered into a securities purchase agreement for an oversubscribed private placement financing, expected to generate approximately $275 million in gross proceeds. The Private Placement is expected to close on or about July 28, 2026.
Entera's lead drug candidate is EB613, the first oral anabolic (bone-building) tablet in development for the treatment of osteoporosis. The company plans to initiate a Phase 3 clinical trial in late 2026, with topline results expected in the second half of 2028.
ENTX closed Monday's trading at $3.92, up 91.22%.
GOSS To File Seralutinib NDA in September
Gossamer Bio, Inc. (
GOSS
), on Monday, announced several regulatory, strategic, and corporate updates.
A New Drug Application (NDA) for Seralutinib to treat pulmonary arterial hypertension (PAH) is expected to be filed in September 2026, following a productive Pre-NDA Type B meeting with the FDA and receipt of the official meeting minutes.
The company has also regained worldwide development and commercialization rights to Seralutinib from Chiesi. In addition, shareholders have approved proposals related to the company's previously announced convertible note exchange and authorised a reverse stock split.
Cash, cash equivalents and marketable securities totaled approximately $57 million as of June 30, 2026, according to the company.
GOSS closed Monday's trading at $0.19, up 46.62%.
FBRX Scooped Up
Forte Biosciences Inc. (
FBRX
) has agreed to be acquired by argenx (ARGX) for $77 per share in cash, representing a total equity value of roughly $2.2 billion.
This clinical-stage biopharmaceutical company is advancing FB102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potential broad autoimmune and autoimmune-related indications. The acquisition is expected to close in Q3 2026.
FBRX closed Monday's trading at $76.50, up 39.65%.
TVGN On Watch
Tevogen Bio Holdings Inc. (
TVGN
) jumped more than 24% on Monday on no specific news.
Last month, the company launched a new healthcare services initiative as part of its strategy to expand into a broader, revenue-generating healthcare
business
. The initiative is being led on an interim basis by Vice President of Strategic Initiatives William Keane.
As part of this effort, the company is evaluating the acquisition of a Management Services Organization (MSO) and a Contract Research Organization (CRO). If completed, these acquisitions could generate approximately $100 million in combined annual revenue while supporting Tevogen's goal of improving healthcare affordability and access.
The company's Annual Meeting of Stockholders is scheduled for Monday, August 24, 2026.
TVGN closed Monday's trading at $5.57, up 24.05%.
TRAX Races Higher
First Tracks Biotherapeutics Inc. (
TRAX
), a recent spin-off of AnaptysBio, Inc. (ANAB), has been firing on all cylinders since its Nasdaq debut on April 20, 2026.
This clinical-stage biotechnology company is advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease and eosinophilic esophagitis; Rosnilimab, a pathogenic T cell depleter, which has completed a Phase 2b trial for rheumatoid arthritis; and ANB101, a BDCA2 modulator, in a Phase 1a trial.
TRAX closed Monday's trading at $42.03, up 18.33%.
Rival setback fuels Omeros rally
Shares of Omeros (
OMER
) jumped more than 15% on Monday after AstraZeneca (AZN) reported that its rare disease drug Ultomiris failed to meet the primary endpoint in a Phase 3 trial for hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).
Omeros
markets
FDA-approved YARTEMLEA, a treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), and the failure of AstraZeneca's Ultomiris removes a key near-term competitive threat to the drug, according to analysts at H.C. Wainwright.
OMER closed Monday's trading at $11.34, up 15.83%.
Did you know?
Although 7 to 9 hours of sleep at night is generally recommended for adults, a small group of people, known as Natural Short Sleepers (NSS), defies this rule.
These individuals naturally need only 4 to 6 hours of sleep a night throughout their lives. Unlike people who are sleep-deprived, natural short sleepers do not experience the usual negative effects of too little sleep. They also do not feel the need to sleep longer and may even feel worse if they do. So, what causes this?
Research has linked NSS to mutations in several genes, including DEC2, ADRB1, NPSR1, and GRM1. More recently, scientists identified a mutation in the salt-induced kinase 3 (SIK3) gene (hSIK3-N783Y) in a person with the natural short sleep trait, adding another genetic factor associated with the condition. (Source: Proceedings of the National Academy of Sciences (2025))
For comments and feedback contact: editorial@rttnews.com
Business News
Biotech Stocks Facing FDA Decision In July 2026
Biotech Stocks Facing FDA Decision In June 2026
Biotech Stocks Facing FDA Decision In May 2026
Latest Updates on Middle East War
U.S. Dollar Ticks Higher As Easing Middle East Tensions Lowers Fed Rate Hike Expectations
July 27, 2026 17:00 ET
Canadian Stocks Edge Higher Amid Easing Middle East Tensions
July 27, 2026 16:26 ET
Crude Oil Nosedives As Middle East Tension Eases After U.S. And Iran Pause Mutual Attacks
July 27, 2026 14:36 ET
Gold Inches Higher As Middle East Tensions Ease, Crude Oil Plunges Sharply
July 27, 2026 13:40 ET
U.S. Dollar Ticks Higher As U.S. Steps Up Threats On Iran While Crude Oil Prices Plunge
July 24, 2026 17:00 ET
View More
Global Economics Weekly Update - July 20 – July 24, 2026
July 25, 2026 02:46 ET
The latest policy decision from the European Central Bank dominated the scene this week that was relatively slow for economics news flow. In the U.S., main highlights were the weekly initial jobless claims and new home sales data. In Europe, the ECB rate decision and the latest inflation figures from the U.K. drew attention. In Asia, results of a private sector survey from India were in focus.
View More Videos
RELATED NEWS
Latest Updates on COVID-19
KFF Poll Finds AI Health Chatbot Users More Likely To Believe Vaccine Myths
July 01, 2026 14:27 ET
Editor's Pick
Most Read
Most Emailed
AstraZeneca Q2 Pre-tax Profit Down, But EPS Rise; Backs Positive FY26 View
July 27, 2026 04:19 ET
Verizon Lifts FY26 View Despite Weak Q2, Expands Buyback To Up To $4.5 Bln; Shares Up
July 24, 2026 10:21 ET
EU Commission Flags TikTok's Minor Account Safety Gaps
July 24, 2026 09:56 ET
Volkswagen Cuts FY26 Revenue View After Weak Q2 Profit, Volume
July 24, 2026 05:33 ET
T-Mobile US Q2 Profit Edges Up, Net Additions Drop, Backs FY26 View; Stock Down
July 23, 2026 09:43 ET
GE Vernova Q2 Profit, Orders Climb; Backs FY26 Margin View, Lifts Revenue Forecast; Stock Down
July 22, 2026 07:33 ET
AT&T Reiterates FY26 Outlook - Update
July 22, 2026 07:02 ET
OpenAI Says Advanced AI Models Escaped Test Environment In Cybersecurity Incident
July 22, 2026 17:46 ET
WSP Raises Arcadis Acquisition Offer To €51.50 After Initial Rejection
July 24, 2026 11:50 ET
Amapá Minerals Reveals Pricing Of IPO Of 127.27 Mln Common Shares At $1.10/Shr
July 24, 2026 01:42 ET
Union Pacific Signs MoU With CN Supporting Proposed Norfolk Southern Merger
July 23, 2026 01:19 ET
Eligible Amazon Prime Members Have Until July 27 To Claim Up To $51 In FTC Settlement
July 24, 2026 17:15 ET
ATOSS H1 Profit Rises On Higher Revenue; Maintains FY26, FY27 Forecast
July 24, 2026 02:41 ET
Safety Insurance To Be Acquired By Mapfre In $1.54 Bln All-Cash Deal
July 23, 2026 17:11 ET
Nestlé SA H1 Profit Declines, Confirms FY26 Outlook
July 23, 2026 02:21 ET
Carpenter Technology CEO Brian Malloy Passes Away; Tony Thene Named CEO
July 27, 2026 08:18 ET
Dassault Aviation H1 Profit Jumps; Reaffirms 2026 Sales Outlook
July 22, 2026 13:55 ET
JD Sports Fashion Appoints Darren Shapland As Interim Chair
July 22, 2026 00:36 ET
Moncler Reports Higher Revenue In H1 Amid Board Changes
July 22, 2026 14:00 ET
LG Display Q2 Operating Loss Narrows, Turns To Profit In H1; Stock Gains
July 22, 2026 00:54 ET
Alstom Q1 Sales Rise, Confirms FY27 Outlook
July 22, 2026 14:01 ET
V-ZUG Holding Ltd H1 Profit Rises
July 22, 2026 00:57 ET
Gecina Reports H1 Consolidated Net Loss Despite Higher Recurrent Earnings
July 22, 2026 14:19 ET
GEA Group Q2 Preliminary Sales Improve
July 22, 2026 00:58 ET
Valeo H1 Net Income Rises, Reaffirms FY26 Sales Outlook
Lonza H1 Results Climb, Lifts FY26 CORE EBITDA Margin View, Backs Sales Growth Forecast
July 22, 2026 01:15 ET
Valeo S.A. H1 Sales Decline
July 22, 2026 15:54 ET
VAT Group Agrees To Acquire Atonarp For CHF 110 Mln
July 22, 2026 01:16 ET
Editors Pick
Loading...
Copyright © 2026 RTTNews. All rights reserved.
By using this site, you agree to the
Terms of Service
.
About Us
Privacy
Sitemap